Surgical intervention in relapsed ovarian cancer is beneficial: Pro

Annals of Oncology

Volumn 24, Issue SUPPL.10, 2013, Pages

  Harter, P ^a   Heitz, F ^a   Mahner, S ^b   Hilpert, F ^c   du Bois, A ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Ago score; Cytoreductive surgery; Ovarian cancer; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ADVANCED CANCER; AGO SCORE; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CONSENSUS DEVELOPMENT; CYTOREDUCTIVE SURGERY; HUMAN; KARNOFSKY PERFORMANCE STATUS; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PATIENT PREFERENCE; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SURGICAL APPROACH; SURGICAL RISK; SURVIVAL RATE; SURVIVAL TIME;

AGO SCORE; CYTOREDUCTIVE SURGERY; OVARIAN CANCER; RELAPSE;

FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; RECURRENCE;

EID: 84888256024     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt466     Document Type: Article

References (16)

1. Harter P, Muallem ZM, Buhrmann C et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 2011; 121: 615-619.
2. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483.
3. Harter P, Hilpert F, Mahner S et al. Systemic therapy in recurrent ovarian cancer-actual treatment options and new drugs. Expert Rev Anticancer Ther 2010; 10: 81-88.
4. Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinumsensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011; 22: 39-48.
5. Aghajanian C, Blank SV, GoffBA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045.
6. Baumann KH, Wagner U, du Bois A. The changing landscape of therapeutic strategies for recurrent ovarian cancer. Future Oncol 2012; 8: 1135-1147.
7. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000; 88: 144-153.
8. Chi DS, McCaughty K, Diaz JP et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106: 1933-1939.
9. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009; 112: 265-274.
10. Friedlander M, Trimble E, Tinker A et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011; 21: 771-775.
11. Tian WJ, Jiang R, Cheng X et al. Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. J Surg Oncol 2010; 101: 244-250.
12. Sehouli J, Richter R, Braicu EI et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol 2010; 102: 656-662.
13. Harter P, Hahmann M, Lueck HJ et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 2009; 16: 1324-1330.
14. Harter P, du Bois A, Hahmann M et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13: 1702-1710.
15. Harter P, Sehouli J, Reuss A et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011; 21:289-295.
16. Galaal K, Naik R, Bristow RE et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2010; 6: CD007822.